<DOC>
	<DOCNO>NCT01135563</DOCNO>
	<brief_summary>This study Phase I study use vinblastine sirolimus patient relapse solid tumor include select brain tumor lymphoma . The investigator hypothesis combination administration weekly vinblastine sirolimus safe .</brief_summary>
	<brief_title>Study Vinblastine Sirolimus Pediatric Patients With Recurrent Refractory Solid Tumors Including Central Nervous System Tumors</brief_title>
	<detailed_description>Published data demonstrate survival advantage vinblastine-sirolimus regimen vs single agent orthopotic neuroblastoma mouse model unpublished data support VBL vitro pro-apoptotic plasma concentration 1-2 nM range anti angiogenic concentration 2pM . These plasma concentration achievable 6 mg/m2 ( apoptosis ) 1 mg/m2 VBL regimen ( anti-angiogenesis ) weekly regimen . We expect vinblastine deliver give dose , describe protocol , carry anti-apoptotic antiangiogenic activity . Safety preliminary efficacy drug pediatric tumor support development clinical trial .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Age : 021 year time diagnosis 2 . Diagnosis : Histologic verification either time original diagnosis relapse solid tumor include CNS tumor lymphomas 3 . Disease Status : All refractory/recurrent solid tumor include CNS tumor ( Diffuse Intrinsic Brain Stem Gliomas exclude ) lymphoma relapse , refractory , chemotherapycontaining treatment regimen 4 . Measurable disease : Measurable tumor CT MRI define &gt; 10 mm spiral CT least one dimension 5 . Current disease state must one currently know curative therapy 6 . A negative urine pregnancy test require female participant child bear potential 7 . Organ Function Requirements : adequate liver function define AST ALT &lt; 5 x upper limit normal , bilirubin ≤1.5 X upper limit normal adequate renal function : Serum creatinine &lt; 1.5 X upper limit normal age 8 . Adequate Bone Marrow Function Defined : ANC ≥ 1000/mm3 , platelet ≥ 75,000/mm3 hemoglobin ≥ 90 g/L Transfusions permit meet platelet Hgb criterion , patient know history bone marrow involvement tumor Patients platelet count &lt; 75,000/ mm3 refractory platelet transfusion eligible study Patients require transfusion platelet RBC meet eligibility criterion evaluable platelet hgb/hct hematological toxicity 9 . Lansky Play Score ( patient &lt; 16 year age ) must 50 and/or ECOG performance status ( patient ≥ 16 year age ) must 0 2 10 . Specific requirement Neuroblastoma patient Stratum : MIBG scan positive uptake minimum one site ( MIBG require subject 's neuroblastoma previously determine uptake MIBG measurable disease ) Bone marrow tumor cell see routine morphology ( NSE stain ) bilateral aspirate /or biopsy one bone marrow sample 11 . Written inform consent 1 . Lansky score &lt; 50 % 2 . Investigational Drugs : Patients currently receive another investigational drug ( ) 3 . Previous treatment Vinblastine and/or mTor inhibitor 4 . Anticancer Agents : Patients currently receive anticancer agent . Patients must fully recover effect prior chemotherapy , generally least 3 week recent administration ( 6 week nitrosoureas ) 5 . Infection : Patients uncontrolled infection eligible infection judge well control 6 . Patients , opinion investigator , may able comply safety monitoring requirement study , compliance likely suboptimal 7 . One week usage hematopoietic Growth Factor 8 . Patients refractory platelet transfusion 9 . Brain Stem Glioma patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>CNS Tumors</keyword>
	<keyword>Vinblastine</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
</DOC>